Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

Inclusion Criteria:

• Understands the study procedures and can give signed informed consent which includescompliance with the requirements and restrictions listed in the informed consentform (ICF) and in this protocol.

• Male or female ≥18 years of age.

• Is suspected of having cardiac amyloidosis and is undergoing or will undergo adiagnostic evaluation for cardiac amyloidosis (e.g., echocardiography, CMR, boneavid tracer cardiac SPECT, extracardiac or endomyocardial biopsy, etc.).Participants can be enrolled before or during their diagnostic evaluation forcardiac amyloidosis.

• Able to undergo PET/CT imaging as part of the study, including ability to lie supinefor approximately 1 hour.

• For women of childbearing potential: agreement to remain abstinent (refrain fromheterosexual intercourse) or use contraceptive methods that result in a failure rateof <1% per year during the treatment period and for at least 30 days afteradministration of I-124 evuzamitide.

• For men: agreement to remain abstinent or use contraceptive measures and agreementto refrain from donating sperm

Exclusion Criteria:

• Established diagnosis of cardiac amyloidosis.

• Established diagnosis of systemic amyloidosis (e.g., renal AL or ATTR peripheralneuropathy) without known cardiac involvement. Participants who are amyloid positiveonly with carpal tunnel tissue or laminectomy are allowed as long as they do nothave other known organ involvement.

• Receiving therapy with an approved treatment (e.g., tafamadis) or in a clinicaltrial for treatment for ATTR cardiac amyloidosis at time of enrollment. For AL andATTR: Patients may enter the screening period of a clinical trial for treatmentafter the ICF is signed and participant is enrolled in this trial but may notreceive an experimental therapy until after the Day 30 safety follow-up visit inthis trial.

• Is pregnant or breast-feeding.

• Is mentally or legally incapacitated, has significant emotional problems at the timeof the study, or has a history of psychosis.

• Has a known allergy to potassium iodide.

• Receiving hemodialysis or peritoneal dialysis.

• eGFR less than 15mL/min/1.73m2.

• Myocardial infarction within three (3) months of screening.

• Has severe claustrophobia or any condition, medial or otherwise, that would preventcompletion of the study assessments.

• Has any illness that, in the opinion of the investigator, might confound the resultsof the study or pose additional risk to the participant.

• Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux)within seven (7) days prior to I-124 evuzamitide administration.

• Known uncorrected thyroid disorders (other than mild elevation of thyroidstimulating hormone with normal T4).